FibroGen (FGEN) PT Lowered to $55 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Futures point to higher open as more earnings roll in
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Mizuho Securities Downgrades FibroGen (FGEN) to Neutral
April 7, 2021 6:30 AM EDTMizuho Securities analyst Difei Yang downgraded FibroGen (NASDAQ: FGEN) from Buy to Neutral with a price target of $29.00.
The analyst comments "We are downgrading FGEN shares to Neutral, and reducing our PT from $72 to $29 as we see higher risk and uncertainty around timelines to... More
H.C. Wainwright Downgrades FibroGen (FGEN) to Neutral
April 7, 2021 6:11 AM EDTH.C. Wainwright analyst Edwin Zhang downgraded FibroGen (NASDAQ: FGEN) from Buy to Neutral.
For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.
Shares of FibroGen closed at $25.90 yesterday.
... MoreAfter-Hours Stock Movers 04/06: (NMTR) (UTME) (NCLH) Higher; (FGEN) (FIXX) (PHR) Lower (more...)
April 6, 2021 5:42 PM EDTToday's After-Hours Movers
FibroGen, Inc. (Nasdaq: FGEN) 29.2% LOWER; provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (CKD).
9 Meters Biopharma (NASDAQ: NMTR) 15.3% HIGHER; CEO acquired 100,000 shares and its CFO acquired 50,000, according to filings.
UTime Limited Ordinary Shares (NASDAQ: UTME) 11.5% HIGHER; adds to gains after jumping 875% in IPO... More
FibroGen (FGEN) provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from roxadustat Phase 3 program for the treatment of anemia of CKD
April 6, 2021 4:04 PM EDTFibroGen, Inc. (Nasdaq: FGEN) (the Company) today provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (CKD).
As members of senior management were preparing for the upcoming FDA Advisory Committee meeting, we became aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors, said Enrique Conterno, Chief Executive Officer, FibroGen. While all of the analyses set forth below, including the differences in the stratification factors, were included in the NDA, we promptly... More
